SLU-PP-332: The Exercise Mimetic Targeting ERR Nuclear Receptors for Metabolic Fitness and Longevity

Discovery and Background

SLU-PP-332 is a synthetic small-molecule compound developed by researchers at Saint Louis University, from which its name is derived, and first described in peer-reviewed literature in 2023. It belongs to an emerging class of compounds known as exercise mimetics — agents designed to pharmacologically recapitulate the molecular adaptations that physical exercise produces in muscle, heart, and metabolic tissues. Unlike earlier exercise mimetic candidates that targeted single pathways, SLU-PP-332 was designed to act on a family of nuclear receptors that sit at the convergence point of multiple exercise-responsive transcriptional programs.

The compound's mechanism centers on the estrogen-related receptors (ERRs) — specifically ERRalpha, ERRbeta, and ERRgamma — a family of orphan nuclear receptors so named because of their structural similarity to the estrogen receptor, despite not being activated by estrogen itself. ERRs are master regulators of mitochondrial biogenesis, oxidative metabolism, and the transcriptional response to exercise in skeletal muscle and cardiac tissue. They govern the expression of hundreds of genes involved in fatty acid oxidation, oxidative phosphorylation, and cellular energy homeostasis — the same gene programs that endurance exercise upregulates through pathways including PGC-1alpha co-activation.

The research group led by Thomas Burris at Saint Louis University identified SLU-PP-332 through a drug discovery program aimed at finding pan-ERR agonists — compounds capable of activating all three ERR subtypes simultaneously, which endogenous exercise signaling effectively does through post-translational modification and co-factor recruitment. By pharmacologically activating this convergence point, the researchers hypothesized they could trigger the full transcriptional signature of endurance training in tissues that would otherwise only achieve it through sustained aerobic exercise. Initial preclinical results published in 2023 provided striking support for that hypothesis.

Research Overview

The foundational preclinical data for SLU-PP-332 was published in 2023 in the Journal of Medicinal Chemistry and subsequent journals, describing its effects in rodent models across multiple physiological domains. In sedentary mice treated with SLU-PP-332, skeletal muscle showed significant upregulation of oxidative fiber gene programs, increased mitochondrial density, and enhanced capacity for fatty acid oxidation — changes characteristic of endurance training adaptation. Treated animals demonstrated meaningfully improved treadmill endurance performance compared to untreated controls despite equivalent physical activity levels, confirming that the transcriptional changes were functionally significant.

Cardiac effects were equally notable. SLU-PP-332 treatment produced improvements in cardiac output and exercise tolerance in mouse models, with evidence of enhanced mitochondrial function in cardiomyocytes and reduced pathological remodeling under stress conditions. These findings are particularly relevant given the known cardioprotective effects of regular aerobic exercise and the large population of patients with heart failure or reduced cardiac reserve who cannot achieve therapeutic exercise doses.

Metabolic effects in rodent studies included reduced fat mass, improved insulin sensitivity, and enhanced whole-body glucose disposal — a metabolic profile consistent with regular aerobic training. The compound appeared to shift substrate utilization toward fat oxidation at rest, recapitulating one of the most metabolically beneficial adaptations of endurance fitness. Weight loss effects were observed even in the absence of changes in food intake, suggesting the mechanism operates primarily through increased energy expenditure rather than appetite suppression.

Longevity-relevant findings have emerged from studies in Caenorhabditis elegans and early mammalian aging models, where ERR activation has been associated with extended lifespan through mechanisms overlapping with those of caloric restriction and exercise — most notably mitochondrial quality control, reduced oxidative damage accumulation, and enhanced proteostasis. While human data does not yet exist, the compound has attracted significant attention from longevity researchers given the established relationship between aerobic fitness and longevity outcomes in humans.

Key Mechanisms

Pan-ERR Agonism and Transcriptional Exercise Mimicry

SLU-PP-332 binds and activates all three estrogen-related receptor subtypes — ERRalpha, ERRbeta, and ERRgamma — simultaneously, producing a transcriptional response that closely mirrors the gene expression signature of endurance exercise in muscle and cardiac tissue. ERRs function as ligand-activated transcription factors that, when activated, bind to estrogen response element-related sequences in gene promoters and drive expression of oxidative metabolism, mitochondrial function, and energy substrate utilization genes. The pan-ERR approach is mechanistically important: the three subtypes have partially overlapping but distinct target gene sets, and activating all three together more completely replicates the comprehensive transcriptional remodeling that exercise produces.

Mitochondrial Biogenesis and Oxidative Capacity

A primary downstream effect of ERR activation is the induction of PGC-1alpha target genes governing mitochondrial biogenesis — the process of generating new mitochondria and expanding mitochondrial network density within cells. Increased mitochondrial density is one of the cardinal adaptations of endurance training, directly determining oxidative capacity and fatigue resistance in skeletal and cardiac muscle. SLU-PP-332 treatment in rodent models produced measurable increases in mitochondrial content and in the expression of electron transport chain components, cytochrome oxidase subunits, and fatty acid oxidation enzymes — the molecular infrastructure of aerobic fitness.

Fiber Type Switching and Oxidative Muscle Remodeling

Skeletal muscle fiber composition is a key determinant of metabolic health and endurance capacity. Type I (slow-twitch, oxidative) fibers are fatigue-resistant and metabolically efficient; type II (fast-twitch, glycolytic) fibers are powerful but fatigue quickly and are metabolically less favorable. Endurance training shifts the balance toward type I and oxidative type IIa fibers. ERRgamma in particular is a master regulator of the slow oxidative fiber gene program, and SLU-PP-332's activation of ERRgamma in rodent skeletal muscle produced a measurable shift toward oxidative fiber characteristics, enhancing endurance capacity and fat oxidation at the tissue level.

Fatty Acid Oxidation and Metabolic Substrate Shifting

ERRs directly regulate the expression of genes encoding enzymes in the fatty acid beta-oxidation pathway, including medium-chain acyl-CoA dehydrogenase (MCAD) and long-chain acyl-CoA dehydrogenase (LCAD). By upregulating this pathway, SLU-PP-332 shifts cellular fuel preference toward fat oxidation — increasing the proportion of energy derived from lipid substrates at rest and during moderate activity. This substrate shift is metabolically beneficial across multiple dimensions: it spares glycogen, reduces circulating triglycerides and free fatty acids, and improves insulin sensitivity by reducing lipid accumulation in insulin-sensitive tissues.

Cardiac Energetics and Cardioprotection

The heart is almost entirely dependent on oxidative metabolism and is among the most mitochondria-dense tissues in the body. ERRalpha is highly expressed in cardiac tissue and is a key regulator of cardiac energy metabolism, governing the balance between fatty acid and glucose utilization that determines cardiac efficiency. SLU-PP-332's activation of cardiac ERRs enhances mitochondrial function and metabolic flexibility in cardiomyocytes, improving the heart's capacity to maintain output under stress. In heart failure models, where metabolic dysfunction and mitochondrial impairment are central pathological features, ERR agonism has shown protective effects on cardiac structure and function.

Mitochondrial Quality Control and Longevity Pathways

ERR activation upregulates not only mitochondrial biogenesis but also mitophagy — the selective degradation of damaged or dysfunctional mitochondria — and the broader mitochondrial quality control machinery that prevents accumulation of dysfunctional mitochondria with age. This maintenance of mitochondrial quality is increasingly recognized as a central determinant of cellular aging, and its stimulation by SLU-PP-332 places the compound in mechanistic alignment with established longevity interventions including caloric restriction, rapamycin, and exercise itself. In C. elegans models, ERR pathway activation extended lifespan in a manner dependent on downstream mitochondrial and metabolic adaptations.

Common Applications

Metabolic Disease and Obesity

The most immediately translatable application for SLU-PP-332 is in the treatment of obesity and metabolic syndrome, where its ability to increase fat oxidation, improve insulin sensitivity, and enhance energy expenditure addresses multiple pathological features simultaneously. In populations where physical exercise is limited by musculoskeletal disease, cardiovascular insufficiency, severe obesity, or other barriers, a compound that delivers the metabolic benefits of aerobic training through pharmacological activation of the same transcriptional pathways represents a compelling therapeutic concept. Preclinical data in diet-induced obese mouse models supports meaningful improvements in body composition and metabolic markers.

Heart Failure and Cardiac Rehabilitation

Patients with heart failure have impaired cardiac mitochondrial function and reduced metabolic flexibility that contribute to exercise intolerance and disease progression — and are often unable to achieve the exercise doses that would otherwise benefit them. SLU-PP-332's direct enhancement of cardiac oxidative metabolism and mitochondrial density offers a pharmacological route to cardiac metabolic improvement in this population, potentially complementing or partially substituting for the exercise-based cardiac rehabilitation that remains difficult to implement at therapeutic intensity in advanced heart failure.

Sarcopenia and Age-Related Muscle Decline

The progressive loss of skeletal muscle mass and oxidative capacity with aging — sarcopenia — is a major driver of functional decline, metabolic deterioration, and mortality in older adults. ERR-driven mitochondrial biogenesis and oxidative fiber gene expression directly counters the molecular mechanisms of sarcopenic muscle, which is characterized by mitochondrial dysfunction, reduced PGC-1alpha activity, and fiber type shift toward glycolytic phenotypes. SLU-PP-332 represents a candidate intervention for preserving or restoring muscle metabolic quality in aging populations, alone or in combination with resistance training.

Exercise Performance and Endurance Enhancement

The demonstration that SLU-PP-332 improves treadmill endurance in sedentary rodents has generated interest in its potential for enhancing athletic performance — an application that raises straightforward anti-doping concerns and is unlikely to be a focus of clinical development, but reflects the compound's genuine mechanistic potency. More constructively, it suggests utility as an adjunct to training in populations where exercise capacity is limited, enabling earlier metabolic adaptation than exercise alone would produce and potentially accelerating recovery between training sessions.

Longevity and Healthspan Extension

The convergence of SLU-PP-332's mechanisms — mitochondrial biogenesis, oxidative metabolism enhancement, mitochondrial quality control, and metabolic flexibility — with the established biology of exercise-mediated longevity positions it as a compound of substantial interest in longevity-oriented research and practice. Aerobic fitness is one of the strongest predictors of all-cause mortality across the lifespan, and the molecular pathways SLU-PP-332 activates are the same ones through which exercise confers that survival advantage. Whether pharmacological activation of these pathways produces comparable longevity benefits to the exercise that activates them naturally remains the central question for the field.

References

1. https://pubmed.ncbi.nlm.nih.gov/36989527/
2. https://pubmed.ncbi.nlm.nih.gov/37083946/
3. https://pubmed.ncbi.nlm.nih.gov/12764017/
4. https://pubmed.ncbi.nlm.nih.gov/15175761/
5. https://pubmed.ncbi.nlm.nih.gov/18006707/
6. https://pubmed.ncbi.nlm.nih.gov/22560223/
7. https://pubmed.ncbi.nlm.nih.gov/26017576/
8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4954912/
9. https://pubmed.ncbi.nlm.nih.gov/34255042/
10. https://pubmed.ncbi.nlm.nih.gov/37315524/

Note: This list compiles unique sources referenced throughout the article. For a full bibliography, including additional studies mentioned in the content, consult the original research compilations or databases like PubMed.